Journal of Clinical Oncology, Vol 16, 405-410, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

PG Rose, JA Blessing, AR Mayer and HD Homesley
Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, OH, USA.

PURPOSE: A phase II trial was conducted to determine the activity of prolonged oral etoposide in platinum-resistant and platinum-sensitive ovarian carcinoma. PATIENTS AND METHODS: Platinum-resistant disease was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. The starting dose was 50 mg/m2/d (30 mg/m2/d for prior radiotherapy) for 21 days, every 28 days. A dose escalation to a maximum dose of 60 mg/m2/d was prescribed. RESULTS: Of 99 patients entered, 97 were assessable for toxicity and 82 were assessable for response. Among 41 platinum-resistant patients a 26.8% response rate (7.3% complete response [CR] and 19.5% partial response [PR] rate) occurred. The median response duration was 4.3 months (range, 1.3 to 8.7), median progression-free interval (PFI) was 5.7 months (range, 0.8 to 30.8+), and median survival time was 10.8 months (range, 1.9 to 45.8). Twenty-five of 41 platinum-resistant patients had also previously received paclitaxel; of which eight (32%) responded. Among 41 platinum-sensitive patients, a 34.1% response rate (14.6% CR and 19.5% PR rate) occurred. The median response duration was 7.5 months (range, 1.9 to 15.2+), median PFI was 6.3+ months (range, 0.9 to 20.4), and median survival time was 16.5+ months (range, 0.9 to 34.8). Of 97 patients assessable for toxicity, grade 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12%), neutropenia in 45.4% (grade 3, 20%; grade 4, 25%), thrombocytopenia in 9% (grade 3, 5%; grade 4, 4%), and anemia in 13.4%. Three treatment-related deaths occurred: two from neutropenic sepsis and one from thrombocytopenic bleeding after an overdose. One patient developed leukemia. CONCLUSION: This regimen is active in platinum- resistant and platinum-sensitive ovarian carcinoma. Additionally, the regimen is active in paclitaxel-resistant ovarian carcinoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M. Del Campo, A. Roszak, M. Bidzinski, T. E. Ciuleanu, T. Hogberg, M. Z. Wojtukiewicz, A. Poveda, K. Boman, A. M. Westermann, C. Lebedinsky, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer Ann. Onc., November 1, 2009; 20(11): 1794 - 1802. [Abstract] [Full Text] [PDF]

				D. S. Miller, J. A. Blessing, C. N. Krasner, R. S. Mannel, P. Hanjani, M. L. Pearl, S. E. Waggoner, and C. H. Boardman Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group J. Clin. Oncol., June 1, 2009; 27(16): 2686 - 2691. [Abstract] [Full Text] [PDF]

				G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]

				M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]

				T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al. Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models Endocrinology, April 1, 2006; 147(4): 1761 - 1769. [Abstract] [Full Text] [PDF]

				S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al. Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				P. G. Rose Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer Oncologist, March 1, 2005; 10(3): 205 - 214. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer Ann. Onc., July 1, 2003; 14(7): 1094 - 1099. [Abstract] [Full Text] [PDF]

				M. A. Bookman Developmental Chemotherapy and Management of Recurrent Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167. [Abstract] [Full Text] [PDF]

				M.-C. Le Deley, T. Leblanc, A. Shamsaldin, M.-A. Raquin, B. Lacour, D. Sommelet, A. Chompret, J.-M. Cayuela, C. Bayle, A. Bernheim, et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Societe Francaise d'Oncologie Pediatrique J. Clin. Oncol., March 15, 2003; 21(6): 1074 - 1081. [Abstract] [Full Text] [PDF]

				T. J. Herzog Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 3 - 10. [Abstract] [Full Text] [PDF]

				C. J. Dunton Management of Treatment-Related Toxicity in Advanced Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 11 - 19. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease Oncologist, October 1, 2002; 7(90005): 20 - 28. [Abstract] [Full Text] [PDF]

				R. F. Ozols Recurrent Ovarian Cancer: Evidence-Based Treatment J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163. [Full Text] [PDF]

				D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1238 - 1247. [Abstract] [Full Text] [PDF]

				A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322. [Abstract] [Full Text] [PDF]

				A. N. Gordon, C. O. Granai, P. G. Rose, J. Hainsworth, A. Lopez, C. Weissman, R. Rosales, and T. Sharpington Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer J. Clin. Oncol., September 17, 2000; 18(17): 3093 - 3100. [Abstract] [Full Text] [PDF]

				P. G. Rose, M. Rodriguez, S. Waggoner, B. E. Greer, I. R. Horowitz, J. M. Fowler, and W. P. McGuire Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., August 16, 2000; 18(16): 2957 - 2962. [Abstract] [Full Text] [PDF]

				M. Seiden Highlights in Ovarian Cancer Oncologist, August 1, 2000; 5(4): 267 - 273. [Abstract] [Full Text]

				G. Toffoli, R. Sorio, P. Aita, D. Crivellari, G. Corona, A. Bearz, I. Robieux, A. M. Colussi, F. Stocco, and M. Boiocchi Dose-finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients Clin. Cancer Res., June 1, 2000; 6(6): 2279 - 2287. [Abstract] [Full Text]

				M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al. Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202. [Abstract] [Full Text] [PDF]

				M. Markman and M. A. Bookman Second-Line Treatment of Ovarian Cancer Oncologist, February 1, 2000; 5(1): 26 - 35. [Abstract] [Full Text]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				M. A. Bookman Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Oncologist, April 1, 1999; 4(2): 87 - 94. [Abstract] [Full Text]

				S. A. Cannistra Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited J. Clin. Oncol., March 1, 1999; 17(3): 741 - 741. [Full Text] [PDF]